STERIS plc (STE) stock
STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 21/303% below fair value
$256.27−0.85 (-0.33%)
Close on Nov 11, 2026Market cap $24.99BP/E 30.4Yield 0.96%
Steris EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Steris's EPS for the twelve months ending Sep 30, 2026 was $8.43, up 21.3% year over year. For fiscal 2026 it was $7.93, up 27.9% from the year before. The highest annual figure on record is $7.93 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $7.93 | +27.9% |
| FY2025 | Mar 31, 2025 | $6.20 | +62.7% |
| FY2024 | Mar 31, 2024 | $3.81 | +256.1% |
| FY2023 | Mar 31, 2023 | $1.07 | -56.9% |
| FY2022 | Mar 31, 2022 | $2.48 | -46.4% |
| FY2021 | Mar 31, 2021 | $4.63 | -2.7% |
| FY2020 | Mar 31, 2020 | $4.76 | +34.1% |
| FY2019 | Mar 31, 2019 | $3.55 | +4.7% |
| FY2018 | Mar 31, 2018 | $3.39 | +164.8% |
| FY2017 | Mar 31, 2017 | $1.28 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $2.19 | +12.9% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $2.04 | +14.0% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $2.24 | +52.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.96 | +12.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.94 | +28.5% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.79 | +22.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $1.47 | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.75 | +23.2% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.51 | +30.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $1.46 | +16.8% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$0.01 | -100.5% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $1.42 | +14.5% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $1.16 | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.25 | +13.6% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $1.88 | +261.5% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $1.24 | -12.7% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$3.15 | -556.5% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $1.10 | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $0.52 | -49.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $1.42 | +6.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $0.69 | -43.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$0.24 | -122.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $1.02 | -28.7% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $1.33 | +8.1% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $1.23 | +10.8% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $1.05 | +5.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $1.43 | +12.6% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $1.23 | +119.6% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $1.11 | +22.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $1.00 | +22.0% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $1.27 | +47.7% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $0.56 | -49.5% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $0.91 | +33.8% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $0.82 | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $0.86 | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $1.11 | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $0.68 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?